50, 100, 150 & 200 mg
Four approved tablet strengths support initiation, titration and maintenance dosing.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (50 mg, 100 mg, 150 mg, 200 mg), By Application (Partial-Onset Seizures, Primary Generalized Tonic-Clonic Seizures), By Patient Group (Adults, Adolescents, Pediatric Patients), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Manufacturer Type (Originator / Branded Supplier, Large Generic Manufacturers, Regional Generic Manufacturers), and Regional Forecast, 2026-2034
The global lacosamide tablets market was valued at USD 376.0 million in 2025 and is estimated at USD 396.0 million in 2026. The market is projected to reach USD 706.3 million by 2034, representing a 7.5% CAGR during 2026–2034.
Lacosamide is an antiseizure medicine used for partial-onset seizures and as adjunctive therapy for primary generalized tonic-clonic seizures. The tablet market is centered on 50 mg, 100 mg, 150 mg and 200 mg film-coated oral strengths supplied under the VIMPAT brand and a broad range of approved generic products.
The underlying epilepsy burden remains substantial. WHO states that around 50 million people worldwide have epilepsy and that up to 70% could become seizure-free with appropriate diagnosis and treatment. This creates a large long-term demand base for established antiseizure medicines, including lacosamide, particularly as access improves in low- and middle-income countries.
Generic competition transformed the commercial structure after FDA first approved multiple generic lacosamide tablets in March 2022. Current 2026 DailyMed labels from Aurobindo, Camber and other manufacturers show active generic supply across the standard tablet strengths, while VIMPAT labeling covers partial-onset seizures from one month of age and adjunctive treatment of primary generalized tonic-clonic seizures from four years of age.
Source: WHO epilepsy; VIMPAT current label; Aurobindo lacosamide; Camber lacosamide; FDA first generic approvals.
The study defines the global lacosamide tablets market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | 50 mg; 100 mg; 150 mg; 200 mg |
| By Application | Partial-Onset Seizures; Primary Generalized Tonic-Clonic Seizures |
| By Patient Group | Adults; Adolescents; Pediatric Patients |
| By Distribution Channel | Hospital Pharmacies; Retail Pharmacies; Online Pharmacies |
| By Manufacturer Type | Originator / Branded Supplier; Large Generic Manufacturers; Regional Generic Manufacturers |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; United Kingdom; France; Italy; China; Japan; India; South Korea; Brazil; Mexico and other relevant markets |
| Key Market Players | UCB; Sun Pharmaceutical Industries; Viatris; Teva Pharmaceutical Industries; Dr. Reddy's Laboratories; Aurobindo Pharma; Cipla; Lupin; Torrent Pharmaceuticals; Glenmark Pharmaceuticals; Hetero; Amneal Pharmaceuticals |
The market includes finished-dose oral lacosamide tablets used for approved epilepsy indications. Revenue covers branded and generic 50 mg, 100 mg, 150 mg and 200 mg tablet strengths.
Lacosamide oral solution, intravenous lacosamide, unrelated antiseizure medicines and off-label use outside the approved seizure indications are outside the core tablet revenue boundary.
WHO reports around 50 million people living with epilepsy worldwide, creating a large recurring market for antiseizure medicines.
FDA approved multiple first generic lacosamide tablet products in March 2022. Broader manufacturer participation has lowered barriers to long-term use and increased payer choice.
Current U.S. labels cover partial-onset seizures from one month of age and adjunctive treatment of primary generalized tonic-clonic seizures from four years of age.
Lacosamide tablets are taken on a continuing schedule in patients who respond, creating regular refill demand across retail, hospital and digital pharmacy channels.
Lacosamide remains a Schedule V controlled substance in the United States, adding prescribing and dispensing requirements beyond ordinary chronic medicines.
Source: WHO; VIMPAT; FDA generics; Aurobindo.
Multiple approved suppliers market the same four core tablet strengths, shifting competition from brand differentiation toward price, pharmacy coverage and supply continuity.
Current labeling reaches infants for partial-onset seizures, increasing the relevance of weight-based dosing and specialist pediatric neurology.
Long-term oral therapy is well suited to recurring community and mail-order dispensing once the regimen is established.
UCB’s VIMPAT remains the reference listed product while generic manufacturers compete through therapeutically equivalent ANDAs.
WHO highlights a large treatment gap in lower-income countries, making affordable generic antiseizure therapy an important long-term volume driver.
Lacosamide tablets are a mature oral dosage form, so commercial differentiation is concentrated in dose strength, manufacturing quality, pack size and supply reliability.
Four approved tablet strengths support initiation, titration and maintenance dosing.
Twice-daily oral tablets provide a straightforward chronic epilepsy treatment format.
Generic products must demonstrate bioequivalence to the reference listed drug before U.S. approval.
Stable maintenance therapy creates recurring pharmacy demand over long treatment periods.
By type, the market is segmented into 50 mg, 100 mg, 150 mg and 200 mg tablets. The 100 mg strength is the leading segment because it is central to adult initiation and maintenance dosing.
The 50 mg tablet supports adjunctive initiation, pediatric or lower-dose regimens and flexible titration.
The 100 mg tablet is widely used in adult monotherapy initiation and ongoing twice-daily maintenance.
The 150 mg tablet provides a higher maintenance step while reducing the number of tablets needed per dose.
The 200 mg tablet supports upper maintenance doses and can reduce pill burden in patients requiring higher daily exposure.
The 100 mg strength should remain the broadest routine segment, while the full four-strength portfolio supports individualized titration.
By application, the market is segmented into partial-onset seizures and primary generalized tonic-clonic seizures. Partial-onset seizures are the leading application because lacosamide is approved for both monotherapy and adjunctive treatment in this indication.
Lacosamide is approved for treatment of partial-onset seizures from one month of age and can be used as monotherapy or adjunctive therapy depending on age and clinical setting.
Lacosamide is approved as adjunctive treatment for primary generalized tonic-clonic seizures from four years of age.
Partial-onset seizures will remain the largest application because of broader use across monotherapy and adjunctive treatment.
By patient group, the market is segmented into adults, adolescents and pediatric patients. Adults remain the largest treated group, while pediatric use is an important access-expansion segment.
Adults represent the largest diagnosed and treated population and use the full range of tablet strengths.
Adolescents require long-term seizure control and adherence through school, driving and early employment transitions.
Current partial-onset seizure labeling extends to one month of age, although younger children may require non-tablet dosage forms depending on weight and swallowing ability.
Adults will remain the largest tablet user group, while pediatric labeling strengthens long-term brand and generic demand as patients transition to tablets.
By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Retail pharmacies lead because lacosamide tablets are primarily used as chronic outpatient therapy.
Hospital pharmacies support therapy initiation, specialist neurology care and transitions after inpatient treatment.
Community pharmacies handle most recurring tablet prescriptions once treatment is established.
Mail-order and digital pharmacy channels improve refill convenience for chronic treatment where controlled-substance rules permit.
Retail pharmacies will remain the largest channel, while online dispensing should gain share within applicable regulatory limits.
By manufacturer type, the market is segmented into the originator or branded supplier, large generic manufacturers and regional generic manufacturers. Large generics dominate unit volume after patent expiry.
UCB’s VIMPAT remains the reference product and retains brand recognition in specialist neurology.
Sun Pharma, Viatris, Teva, Dr. Reddy’s, Aurobindo, Cipla, Lupin and other large manufacturers compete across major regulated markets.
Regional suppliers expand access through local tenders, pharmacy relationships and lower-cost manufacturing.
Large generic manufacturers will remain the dominant volume segment, while VIMPAT retains a reference-brand role.
Regional demand follows epilepsy diagnosis, treatment access and generic penetration. North America is the largest market, while Asia-Pacific provides the strongest long-term patient-volume opportunity.
The United States has broad generic availability, specialist neurology access and established reimbursement for chronic antiseizure therapy.
European epilepsy care combines branded and generic lacosamide with broad retail-pharmacy access.
India, China and other populous markets combine large epilepsy populations with expanding generic manufacturing and treatment access.
Brazil and Mexico support growing access through generic neurology portfolios.
The largest opportunity is improved diagnosis and access in settings where WHO continues to identify major epilepsy treatment gaps.
Source: WHO; FDA generics; DailyMed Aurobindo.
Lacosamide tablets are prescription antiseizure medicines with a mature reference-product and ANDA-based generic market.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| Reference product | VIMPAT was initially approved in the United States in 2008. | Provides the regulatory reference for generics. |
| First generics | FDA approved multiple 50 mg, 100 mg, 150 mg and 200 mg lacosamide tablets in March 2022. | Created broad generic competition. |
| Current indications | DailyMed labels include partial-onset seizures and adjunctive primary generalized tonic-clonic seizure treatment. | Defines the commercial clinical scope. |
| Controlled substance | Lacosamide is Schedule V in the United States. | Adds controlled-dispensing requirements. |
Source: VIMPAT; FDA generic approvals; FDA ANDA.
The market is highly genericized, with supplier competition based on cost, regulatory approvals, pharmacy access and supply reliability.
VIMPAT remains the branded reference product across tablet and other lacosamide dosage forms.
Large generics compete through broad regulatory portfolios and international distribution.
Additional suppliers intensify price competition and strengthen supply redundancy.
Source: VIMPAT; Aurobindo; Camber; FDA generics.
June 2026: Aurobindo Pharma’s current U.S. DailyMed label was updated, showing active ANDA supply across standard lacosamide tablet strengths.
June 2026: Camber Pharmaceuticals maintained active lacosamide tablet listings across multiple NDC pack sizes and all four core strengths.
May 2026: The current VIMPAT DailyMed labeling continued to support partial-onset seizure treatment from one month of age and adjunctive primary generalized tonic-clonic seizure treatment from four years.
Current generic environment: The multi-supplier market established by FDA’s 2022 first-generic approvals continues to shape pricing and distribution.
Source: Aurobindo; Camber; VIMPAT; FDA generics.
The global lacosamide tablets market market is projected to grow from USD 396.0 million in 2026 to USD 706.3 million by 2034, at a 7.5% CAGR during 2026–2034. Growth is expected to be supported by the large global epilepsy population, improved treatment access and continued use across adult and pediatric seizure disorders. Generic competition should keep pricing under pressure while expanding patient volume.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Epilepsy burden | WHO reports around 50 million people with epilepsy. | Supports chronic demand. |
| Generic access | Multiple manufacturers reduce cost barriers. | Expands treatment. |
| Pediatric indication | Current labels cover younger patients. | Broadens lifetime use. |
| Chronic refills | Twice-daily oral therapy creates recurring dispensing. | Supports stable volume. |
| Emerging markets | Treatment gaps remain large in lower-income countries. | Creates long-term access opportunity. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global lacosamide tablets market landscape.
24LifeScience develops lacosamide tablets market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis combines current WHO epilepsy evidence, current DailyMed prescribing information and FDA generic-approval records. The displayed 2026 and 2034 values reconcile to a 7.5% CAGR.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 376.0 million in 2025 and is estimated at USD 396.0 million in 2026. It is projected to reach USD 706.3 million by 2034 at a 7.5% CAGR during 2026–2034.
The 100 mg strength is the leading dosage segment because it is widely used in adult initiation and maintenance regimens.
Partial-onset seizures lead because lacosamide is approved for both monotherapy and adjunctive treatment in this indication.
North America is the largest regional market, supported by broad generic availability and established neurology care.
Current U.S. tablet products are available in 50 mg, 100 mg, 150 mg and 200 mg strengths.
Yes. Current labeling covers partial-onset seizures from one month of age and adjunctive treatment of primary generalized tonic-clonic seizures from four years.
FDA approved multiple first-generic lacosamide tablet products in March 2022.
The report profiles UCB, Sun Pharma, Viatris, Teva, Dr. Reddy’s, Aurobindo, Cipla, Lupin, Torrent, Glenmark, Hetero and Amneal.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.